A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries a risk of bleeding and infection. Findings from this research may offer a more accurate and reliable method to diagnose prostate cancer.
“This study is exciting because it has the potential to offer a non-invasive alternative to the traditional PSA test in order to diagnose significant prostate cancers,” said Craig Rogers, M.D., chair of the Vattikuti Urology Institute at Henry Ford Health System. “The discovery of new biomarkers ultimately benefits our patients, as it advances our understanding of this complex disease and how to most effectively treat it.”
When the KLK4 protein coding gene and KLKP1 pseudogene fuse together, the fusion gene KLK4-KLKP1 is formed. Pseudogenes like KLKP1 are the non-functional, or dead, versions of an actual gene that is normally not expressed in a cell but can become active in cancerous cells and disrupt the functions of the actual gene.
“The unique feature of this fusion gene is the conversion of the noncoding pseudogene KLKP1 into a protein coding gene, and its unique expression in about 30 percent of high Gleason grade prostate cancer,” said Dr. Palanisamy. “Like other ETS family gene fusions, KLK4-KLKP1 can also be detected in the urine samples of patients with prostate cancer, enabling non-invasive detection of prostate cancer. Given the unique feature of this fusion, prostate cancer specific expression, oncogenic properties and noninvasive detection, this novel gene fusion has the potential to be used as a biomarker for early detection of prostate cancer and a therapeutic target.”
The researchers conducting this study screened a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients of other races), which revealed that the KLK4-KLKP1 fusion gene is expressed in about 32 percent of prostate cancer patients, representing a distinct subset of prostate cancer cases. Correlative analysis showed that the new fusion gene can be used in combination with other prostate cancer molecular markers for cancer detection. In addition to urine samples, the fusion could also be detected in needle biopsy tissue samples by using a specific antibody.
Prostate cancer is the most common cancer among men in the United States. Advances in diagnosis, treatment, and management have resulted in increased survival rates, yet prostate cancer still remains the second leading cause of cancer-related deaths among American men. One of the major barriers to achieving successful prostate cancer control is the underlying molecular complexity of the disease itself.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Thank you, Dad, for a cancer cure: Barbara Hertzon June 20, 2021 at 6:09 am
Radioiodine has been used for decades to diagnose and treat thyroid cancer, the first of today’s “theranostics,” combining “therapy” and “diagnosis.” Here’s a shoutout of gratitude this Father’s Day, ...
- Bright White Light May Offset Negative Effects of ADT in Older Men With Prostate Canceron June 20, 2021 at 3:00 am
Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.
- Prostate cancer focus of initiative: 'I was a ticking time bomb'on June 19, 2021 at 2:06 pm
When Anthony Bridges' wife suggested a doctor's visit, it wasn't an immediate priority for the Albany resident. She persisted, however, and that effort may have saved his life. "She said, 'You haven't ...
- Overcoming a newly recognized form of resistance to modern prostate cancer drugson June 18, 2021 at 10:38 am
While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer—androgen receptor inhibitors such as enza ...
- Rep. La Shawn Ford shares prostate cancer diagnosison June 17, 2021 at 3:47 pm
Cancer-free and ready to talk about it, Rep. La Shawn Ford shared his very personal story after being diagnosed with prostate cancer in October 2020.
- Drug for advanced prostate cancer receives FDA 'breakthrough therapy' designation to speed up development after study found men given the treatment had a nearly 40% reduced ...on June 17, 2021 at 2:24 pm
PSMA-617, were 38% less likely to die and lived on average four months longer than the control arm according to clinical trial results from Novartis released in June.
- Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseaseson June 17, 2021 at 10:15 am
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...
- Mayo Clinic Q&A: Advances in ablation for prostate canceron June 15, 2021 at 9:15 pm
My husband was diagnosed with prostate cancer, and we are looking at treatment options. One doctor suggested a prostatectomy, but my husband finds ablation appealing because of quality of life ...
- PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regionson June 15, 2021 at 1:50 pm
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.
via Bing News